Life Sciences industry leader joins the region’s Life Science & Healthcare membership organisation
Cambridge, UK: 10 April 2024
EMBL-EBI and Wellcome Trust Sanger Institute share the Wellcome Genome Campus. This proximity fosters close collaborations and contributes to an international and vibrant campus environment. Researchers are supported by easy access to scientific expertise, well-equipped facilities and an active seminar programme.
The EMBL-EBI–Sanger Postdoctoral (ESPOD) Programme builds on the strong collaborative relationship between the two institutes, offering projects which combine experimental (wet lab) and computational approaches.
At Cancer Research UK, we exist to beat cancer.
We have an exciting opportunity at Cancer Research Horizons for a skilled Principal scientist to join the Joint AstraZeneca-Cancer Research Horizons Functional Genomics Centre based in Cambridge.
About Iso
Isomorphic Labs (IsoLabs) was launched in 2021 to advance human health by building on and beyond the Nobel-winning AlphaFold system. Since then, our interdisciplinary team of drug discovery experts and machine learning specialists has built powerful new predictive and generative AI models that accelerate scientific discovery at digital speed.
Offers UK academic, biotech and biopharma researchers direct access to specialist project support, 10x Genomics Chromium Single Cell-based workflows, sequencing infrastructure and bioinformatics expertise
Pioneer Group has announced the launch of new regional accelerator programmes designed to support early-stage life science and tech companies accelerate their journey to market.
Pioneer delivers the most comprehensive suite of accelerator and venture building activity across the UK and Ireland, helping founders to transfer cutting-edge discovery into visionary ventures that scale. To date, Pioneer has supported more than 350 entrepreneurs and funded over 195 companies, which have collectively raised £830 million in investment.
About the Role
Scendea is seeking a highly motivated individual to join our global team as a full-time Principal Consultant (CMC, small molecules experience). The ideal candidate will have a proven track record in CMC for small molecule drug development, with expertise in process development, scale-up, regulatory submissions, and the pre-approval life cycle management of small molecule products. This is a hybrid position, affiliated to either of our UK or Australia offices, with a requirement to work in the office a minimum of one day per month.
Cambridge, UK – 22 July, 2026 – Healx, an AI-powered, clinical-stage biotech company dedicated to rare diseases, today announced that the first patient has been dosed in its Phase 1/2 dose-escalation and dose-confirmation clinical trial to evaluate the safety and efficacy of HLX-4310, an investigational oral combination of a class I selective HDAC inhibitor and an mTOR inhibitor, in adolescents and adults with relapsed, refractory sarcoma, with a focus on osteosarcoma.
Scendea is seeking a Business Support Administrator to join our UK team in a 12-month fixed-term position. The role is full-time, Monday to Friday during standard office hours, and will be based at our Bishop’s Stortford office, with an anticipated start date of September 2026. This position reports into the Business Support Manager.
The successful candidate will be a highly organised professional with experience in systems administration, strong multitasking abilities, and excellent attention to detail.
The Company